Healius Ltd (ASX: HLS) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Healius Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Healius Ltd (ASX: HLS)
Latest News
Healthcare Shares
Healius vs Australian Clinical Labs: Which ASX pathology share wins?
Broker Notes
6 ASX shares upgraded by experts amid a weak market
Broker Notes
Buy, hold, sell: Netwealth, Tabcorp, Healius shares
Broker Notes
Buy, hold, sell: Judo Capital, Healius, BHP shares
ASX Share Market News
ASX 200 healthcare shares soar 9% amid notable FY26 reports from CSL, Pro Medicus
Earnings Results
Healius posts FY26 revenue growth, narrows underlying loss
ASX Share Market News
These are the 10 most shorted ASX shares
ASX Share Market News
Which are the 10 most shorted ASX shares?
Broker Notes
Buy, hold, sell: Southern Cross Gold, Healius, Centuria Office REIT shares
Broker Notes
5 ASX shares downgraded by brokers this week
Broker Notes
Buy, hold, sell: Aristocrat, Breville, and Healius shares
Healthcare Shares
Why is this ASX 300 share crashing over 20% today?
Frequently Asked Questions
-
Yes, Healius has historically paid two fully franked shareholder dividends a year.
-
Healius has generally paid its shareholder dividends in March/April and September/October.
-
Healius Ltd listed on the ASX on 3 July 1998.
Dividend Payment History Data provided by Morningstar.
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| 09 May 2025 | $0.4130 | 100.00% | Special Cash | 23 May 2025 |
| 07 Sep 2022 | $0.0600 | 100.00% | Final | 21 Sep 2022 |
| 24 Mar 2022 | $0.1000 | 100.00% | Interim | 05 Apr 2022 |
| 13 Sep 2021 | $0.0675 | 100.00% | Final | 08 Oct 2021 |
| 25 Mar 2021 | $0.0650 | 100.00% | Interim | 15 Apr 2021 |
| 26 Mar 2020 | $0.0260 | 100.00% | Interim | 15 Oct 2020 |
| 29 Aug 2019 | $0.0340 | 100.00% | Final | 27 Sep 2019 |
| 15 Mar 2019 | $0.0380 | 100.00% | Interim | 26 Mar 2019 |
HLS ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Healius Ltd
Healius Ltd (ASX: HLS) operates a network of pathology laboratories and collection centres across Australia.
The company is Australia's second-largest pathology provider, with around 2,000 collection sites and close to 100 pathology laboratories operating under a portfolio of brand names, including Laverty Pathology, Dorevitch Pathology, QML Pathology, and Western Diagnostic Pathology.
Following the May 2025 sale of its Lumus Imaging business, Healius now focuses on pathology and its bioanalytical laboratory services business, Agilex Biolabs.
HLS Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 29 Oct 2026 | $0.49 | $0.00 | 0.00% | 3,729,256 | $0.48 | $0.50 | $0.47 |
| 28 Oct 2026 | $0.49 | $0.03 | 6.59% | 2,581,816 | $0.45 | $0.49 | $0.45 |
| 27 Oct 2026 | $0.46 | $0.02 | 4.55% | 1,405,985 | $0.44 | $0.46 | $0.44 |
| 26 Oct 2026 | $0.44 | $0.01 | 2.30% | 5,361,335 | $0.44 | $0.45 | $0.41 |
| 23 Oct 2026 | $0.44 | $0.02 | 4.82% | 4,066,471 | $0.41 | $0.45 | $0.41 |
| 22 Oct 2026 | $0.42 | $0.02 | 5.13% | 2,944,131 | $0.39 | $0.42 | $0.39 |
| 21 Oct 2026 | $0.39 | $0.00 | 0.00% | 1,347,356 | $0.39 | $0.41 | $0.39 |
| 20 Oct 2026 | $0.39 | $0.01 | 2.63% | 438,080 | $0.39 | $0.39 | $0.38 |
| 19 Oct 2026 | $0.38 | $0.01 | 2.67% | 2,754,702 | $0.37 | $0.40 | $0.37 |
| 16 Oct 2026 | $0.38 | $0.01 | 2.70% | 1,571,054 | $0.37 | $0.39 | $0.37 |
| 15 Oct 2026 | $0.37 | $-0.01 | -2.63% | 2,953,906 | $0.38 | $0.38 | $0.37 |
| 14 Oct 2026 | $0.38 | $-0.01 | -2.60% | 4,833,748 | $0.38 | $0.39 | $0.37 |
| 13 Oct 2026 | $0.39 | $-0.01 | -2.56% | 10,787,465 | $0.39 | $0.39 | $0.37 |
| 12 Oct 2026 | $0.39 | $0.00 | 0.00% | 2,479,968 | $0.40 | $0.40 | $0.38 |
| 09 Oct 2026 | $0.39 | $-0.01 | -2.50% | 799,109 | $0.40 | $0.40 | $0.39 |
| 08 Oct 2026 | $0.40 | $-0.01 | -2.44% | 1,227,178 | $0.41 | $0.41 | $0.40 |
| 07 Oct 2026 | $0.41 | $0.00 | 0.00% | 2,719,041 | $0.41 | $0.41 | $0.40 |
| 06 Oct 2026 | $0.41 | $0.00 | 0.00% | 4,501,124 | $0.40 | $0.43 | $0.40 |
| 05 Oct 2026 | $0.41 | $0.01 | 2.53% | 1,346,073 | $0.40 | $0.42 | $0.40 |
| 02 Oct 2026 | $0.40 | $-0.02 | -4.76% | 3,334,024 | $0.43 | $0.43 | $0.40 |
| 01 Oct 2026 | $0.42 | $-0.01 | -2.33% | 6,096,510 | $0.43 | $0.44 | $0.42 |
| 30 Sep 2026 | $0.43 | $0.02 | 4.82% | 4,731,644 | $0.42 | $0.44 | $0.41 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 27 Oct 2026 | Paul Anderson | Issued | 117,433 | $45,000 |
Issue of securities. VWAP
|
| 26 Oct 2026 | Christopher Hall | Buy | 35,000 | $15,204 |
On-market trade.
|
| 23 Oct 2026 | Paul Anderson | Issued | 4,469,109 | $1,944,062 |
Director remuneration. 4,469,109 Performance Rights
|
| 23 Oct 2026 | Paul Anderson | Buy | 232,941 | $102,959 |
On-market trade.
|
| 27 Aug 2026 | Sally Evans | Transfer | 67,782 | $29,485 |
As advised by the company. as per announcement 27/08/2026
|
| 27 Aug 2026 | Sally Evans | Transfer | 67,782 | $29,485 |
As advised by the company. as per announcement 27/08/2026
|
| 27 Aug 2026 | Katherine (Kathy) Ostin | Exercise | 22,977 | $9,994 |
Conversion of securities.
|
| 27 Aug 2026 | Katherine (Kathy) Ostin | Buy | 22,977 | $9,994 |
Conversion of securities.
|
| 18 Aug 2026 | Paul Anderson | Expiry | 305,462 | $135,930 |
As advised by the company. rights lapsed
|
| 29 Jun 2026 | Paul Anderson | Expiry | 75,887 | $29,595 |
As advised by the company. 305,462 rights, rights Lapsed
|
| 23 Apr 2026 | Katherine (Kathy) Ostin | Exercise | 22,978 | $12,408 |
Conversion of securities. 22977 Share Rights
|
| 23 Apr 2026 | Katherine (Kathy) Ostin | Issued | 22,978 | $12,408 |
Conversion of securities.
|
| 12 Mar 2026 | Katherine (Kathy) Ostin | Buy | 8,547 | $4,999 |
On-market trade.
|
| 12 Mar 2026 | Steven Rubic | Buy | 130,000 | $77,350 |
On-market trade. Average price
|
| 09 Mar 2026 | Katherine (Kathy) Ostin | Buy | 16,264 | $9,999 |
On-market trade. Average price
|
| 04 Mar 2026 | Katherine (Kathy) Ostin | Buy | 23,079 | $14,999 |
On-market trade. Average price per share
|
| 18 Nov 2025 | Paul Anderson | Buy | 54,431 | $47,899 |
On-market trade.
|
| 10 Nov 2025 | Katherine (Kathy) Ostin | Issued | 45,955 | $39,999 |
Director remuneration. VWAP, 45,955 Share Rights
|
| 31 Oct 2025 | Paul Anderson | Buy | 57,471 | $50,976 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Christopher John Hall | Non-Executive Director | Sep 2025 |
Mr Hall brings to the Board experience across asset management, superannuation and, recently, biotechnology. His career has included roles as Chair, Non Executive Director and Chief Investment Officer, along with senior executive positions in Australia and Hong Kong. Chris current roles include Chair of BiomeBank, Non Executive Director, Investment Committee Chair and Audit Committee Member of AMP Super, Non Executive Director and Chair of the Audit & Risk Committee of Funds SA, Investment Committee Chair of Perks Private Wealth, Member of the Advisory Board to the Long Term Value Fund at Tanarra Capital, and a Member of the Merlon Capital Partners Advisory Board.
|
| Mr Paul Anderson | Chief Executive OfficerManaging Director | Mar 2024 |
Mr Anderson earlier held the position of Group Chief Financial Officer. Paul is a business leader with a background in industries facing disruption. He was previously Chief Executive Officer of Network Ten and more recently, Executive Vice President at Viacom CBS Networks Australia & New Zealand. He also spent more than a decade working abroad at CLS Holdings plc in London and KPMG in New Zealand.
|
| Professor Bruce Gregory Robinson AC | Non-Executive Director | Feb 2026 |
Prof Robinson has 25 years experience as a leader in healthcare. Professor Robinson currently serves on the boards of a number of listed healthcare entities. Professor Robinson former roles include Chair of the Australian Government taskforce of expert clinicians charged with reviewing the Medicare Benefits Schedule, the Medical Benefits Schedule Review Taskforce, and chair of Australias peak advisory and funding body for medical research, the National Health and Medical Research Council. He is a former Dean of the University of Sydney Medical School, the former head of the Cancer Genetics Unit at the Kolling Institute, Royal North Shore Hospital, and the former Head, Division of Medicine, Royal North Shore Hospital.
|
| Ms Kathryn (Kate) Mary McKenzie | Non-Executive ChairmanNon-Executive Director | Feb 2021 |
Ms McKenzie is a Chief Executive Officer and Non-Executive Director. Kates executive career included over 30 years experience in the telecommunication and government sectors in Australia, New Zealand and Hong Kong. Kate held several senior roles at Telstra from 2004 to 2016 the last of which was as Chief Operating Officer and 7 years in senior roles in the NSW Government including as Director General of the NSW Department of Industrial Relations. Kate also served 3 years as Chief Executive Officer of Chorus, New Zealand provider of telecommunications infrastructure before commencing her Non-Executive Director career in 2019. She is a member of both the Risk Management Committee and the People, Governance Committee.
|
| Ms Sally Evans | Non-Executive Director | Aug 2018 |
Ms Evans has over 30 years experience in private, government and social enterprise sectors and has worked in Australia, New Zealand, the United Kingdom and Hong Kong with responsibilities across the Asia Pacific region. Sally is a Non Executive Director of Allianz Australia Life Holdings Ltd and related entities, and a number of Opal Healthcare entities. She is Chair of the People, Governance Committee and a member of the Risk Management Committee.
|
| Ms Katherine (Kathy) Ostin | Non-Executive Director | Dec 2024 |
Ms Ostin was an Audit, Assurance and Risk Consulting Partner at KPMG from 2005 to 2017 and has experience in the aged care and healthcare sectors, having established and led KPMGs Health, Aging and Human Services audit practice from 2006 to 2018. During her 24 years with KPMG, Ms Ostin worked in Australia, the US, Asia and the UK. She is a member of the People, Governance Committee.
|
| Mr Charlie Taylor | Non-Executive Director | Mar 2023 |
Mr Taylor has over 30 years experience in international advisory, having retired, in 2020, as a Senior Partner at McKinsey & Company. He has advised many of Australias private and public sector healthcare organisations on topics including strategy, digital, operations and growth transformations, global expansion and supply chains, mergers and acquisitions and board governance. He is a Senior Advisor at GNG Partners and recently retired as Chair of the NSW Innovation and Productivity Council. He is a member of the People, Governance Committee.
|
| Mr Steven Rubic | Non-Executive Director | Dec 2025 |
Mr Rubic has over 30 years of executive leadership in healthcare including leading national areas of operations. He has held CEO positions at St Vincent and Mater Health Sydney, I MED Radiology Network and Healthscope. Steven is also a Non Executive Director. He is currently a Non Executive Director of the Mater Hospitals Group and CHL aged care business and the Deputy Chair of private equity owned InvoCare.He is a chair of the Risk management committee.
|
| Ms Gillian Maria Nairn | Company Secretary | Sep 2026 |
-
|
| Hon Andrew Peter Thomson | Company Secretary | Oct 2025 |
-
|
| Ms Kylie Brown | Company Secretary | May 2025 |
-
|
| Gillian Maria Nairn | Company Secretary |
-
|
|
| Kylie Brown | Company Secretary |
-
|
|
| Andrew Peter Thomson | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Citicorp Nominees Pty Limited | 235,407,337 | 32.42% |
| HSBC Custody Nominees (Australia) Limited | 169,613,798 | 23.36% |
| J P Morgan Nominees Australia Pty Limited | 86,408,332 | 11.90% |
| BNP Paribas Noms Pty Ltd | 16,634,580 | 2.29% |
| HSBC Custody Nominees (Australia) Limited <NT Comnwlth Super Corp A/C> | 11,649,845 | 1.60% |
| BNP Paribas Nominees Pty Ltd <Agency Lending A/C> | 8,997,573 | 1.24% |
| First Samuel Ltd A/CN 086243567 <ANF ITS MDA Clients A/C> | 7,403,579 | 1.02% |
| Sandhurst Trustees Ltd <Wentworth Williamson A/C> | 4,514,449 | 0.62% |
| Indian Pacific Investments Pty Ltd | 3,986,780 | 0.55% |
| LSND Pty Ltd <LSND A/C> | 2,876,345 | 0.40% |
| Rinrim Pty Ltd | 2,497,161 | 0.34% |
| HSBC Custody Nominees (Australia) Limited A/C 2 | 2,301,158 | 0.32% |
| Mast Financial Pty Ltd <A To Z Investment A/C> | 2,250,000 | 0.31% |
| Kenyon St Medical Centre Pty Ltd | 2,000,000 | 0.28% |
| Kinkora Park Pty Ltd <Hawthorn Super Fund A/C> | 2,000,000 | 0.28% |
| Mr Kim Bee Tan & Mrs Verna Suat Wah Tan <Perfect Pair Super Fund A/C> | 1,800,000 | 0.25% |
| Warbont Nominees Pty Ltd <Unpaid Entrepot A/C> | 1,703,284 | 0.23% |
| Mr Prajwal Subedi | 1,689,000 | 0.23% |
| BNP Paribas Nominees Pty Ltd <IB Au Noms Retailclient> | 1,645,875 | 0.23% |
| Citicorp Nominees Pty Limited <Colonial First State Inv A/C> | 1,501,920 | 0.21% |